A clash is brewing between doctors and patients when it comes to treatment for sleep apnea in those with obesity, a new study ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

Eli Lilly & Co. will only work with telehealth firms that agree to stop selling copycat versions of weight-loss drugs, diminishing the likelihood of a partnership with one most visible players in the ...

NB.1.8.1 has mutations that could increase the virus’s transmissibility and decrease the efficacy of certain neutralizing ...

Health-care companies rose amid sales growth optimism. Drug-store chain CVS Health said it has seen complaints of strong push back from patients on its pharmacy-benefit manager's move to favor Novo ...

Hims & Hers Health Inc (NYSE:HIMS) stock fell 3.8% Tuesday after Eli Lilly and Company (NYSE:LLY) indicated it would not partner with telehealth firms selling copycat versions of weight-loss drugs, ...

Researchers found that injectable GLP-1 receptor agonists for obesity tended to yield smaller reductions in weight in ...

Weight loss injections like Ozempic and Zepbound have taken Hollywood and social media by storm over the last year or so. Personally, I've been on Zepbound for nearly 10 weeks now and I've lost over ...

GoodRx says that with the support of a healthcare team, a clear transition plan, and a few cost-saving tools, you can make ...

Back-to-back studies map complementary hunger and satiety pathways, offering clues to refine weight-loss drugs.

CHICAGO -- Physicians debated the idea of the American Medical Association (AMA) supporting a registry to track adverse ...